For the Inventor, By the Inventor

Enter assignee name

Alpharetta, GA, United States of America

Atherogenics, Inc.

USPTO Granted Patents = 25

Forward Citations = 283

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Charles Q Meng (13 out of 15 patents)

James A Sikorski (8 out of 130 patents)

Patricia K Somers (8 out of 9 patents)

4. M David Weingarten (5 out of 9 patents)

5. Uday Saxena (4 out of 26 patents)

6. Liming Ni (4 out of 4 patents)

7. Lee K Hoong (4 out of 4 patents)

8. Jayraz Luchoomun (3 out of 3 patents)

9. Russell M Medford (3 out of 16 patents)

10. Kimberly J Worsencroft (2 out of 2 patents)

11. Mitchell Glass (2 out of 2 patents)

12. David B Edwards (2 out of 2 patents)

13. R Daniel Beauchamp (1 out of 4 patents)

14. Signe Erickson Varner (1 out of 13 patents)

15. Charles A Kunsch (1 out of 17 patents)

25 patents: Sort by Forward Citations

1. 7375252 - Compounds and method for the inhibition of the expression of VCAM-1 (2008-05-20),

2. 7371895 - Salt forms of poorly soluble probucol esters and ethers (2008-05-13),

3. 7294737 - Process of preparing esters and ethers of probucol and derivatives thereof (2007-11-13),

4. 7273948 - Process of preparing esters and ethers of probucol and derivatives thereof (2007-09-25),

5. 7247714 - Protection against oxidative stress and inflammation by a cytoprotective response element (2007-07-24),

6. 7202247 - 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders (2007-04-10),

7. 7183317 - Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality (2007-02-27),

8. 7173129 - Sulfonamide-substituted chalcone derivatives and their use to treat diseases (2007-02-06),

9. 7094801 - Chalcone derivatives and their use to treat diseases (2006-08-22),

10. 7087645 - Compounds and methods for treating transplant rejection (2006-08-08),

11. 7078431 - 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders (2006-07-18),

12. 7071158 - Antioxidant enhancement of therapy for hyperproliferative conditions (2006-07-04),

13. 6960683 - Salt forms of poorly soluble probucol esters and ethers (2005-11-01),

14. 6887712 - Methods and compositions to lower plasma cholesterol levels (2005-05-03),

15. 6881860 - Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality (2005-04-19),

AtheroGenics, Inc. is a biopharmaceutical company focused on the discovery and development of novel drugs to treat chronic inflammatory diseases. With a commitment to improving patients' lives, AtheroGenics aims to advance innovative therapies that target the underlying mechanisms of various cardiovascular and metabolic disorders, such as atherosclerosis and diabetes. Through rigorous research and clinical trials, the company seeks to contribute to the medical community's understanding of these diseases and offer new treatment options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

25 Patents

#27 in Alpharetta, GA

#261 in Georgia

#12,911 in US

#24,931 in the World

Alpharetta, GA, United States of America

Atherogenics, Inc.

Forward Citations = 283

21 inventors:

Charles Q Meng (13 out of 15 patents)

James A Sikorski (8 out of 130 patents)

Patricia K Somers (8 out of 9 patents)

4. M David Weingarten (5 out of 9 patents)

5. Uday Saxena (4 out of 26 patents)

Please report any incorrect information to support@idiyas.com

Loading…